0GA.F Predilife SA

Healthcare Diagnostics & Research Frankfurt Exchange
0.6800 EUR
Close of Nov 11, 2026
0.6300 3.48
Market cap
EUR 2.68M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 0GA.F undervalued?

Graham number

The Graham number of Predilife SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Predilife SA fundamental analysis

No fundamental analysis for Predilife SA yet.

Predilife SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Predilife SA

Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. It provides breast cancer predictive assessment; and multi-pathology predictive assessment. The company also offers MammoRisk, a breast cancer prediction test based on the patient's individual risk; and DenSeeMammo, a breast density measurement software. Predilife S.A. was incorporated in 2004 and is headquartered in Villejuif, France.

Full company profile